Who is sponsoring NCT03855254?

NCT03855254 is sponsored by Swansea University.

What drugs are being tested in NCT03855254?

Interventions in NCT03855254: communication type.

What condition does NCT03855254 study?

NCT03855254 studies Positive Communication (Primary), Negative Communication, Control Condition.

Is NCT03855254 still recruiting?

NCT03855254 is currently completed. Last updated 26 February 2019.

Last reviewed 2019-02-26 · How we verify

NCT03855254

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychological Context Effects

Completed NA Last updated 26 February 2019

What this trial tests

NA trial testing communication type in Positive Communication (Primary) in 35 participants. Completed in 10 January 2019.

Timeline

1 September 2018

Primary endpoint
5 December 2018

10 January 2019

Quick facts

Lead sponsor	Swansea University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	35
Start date	1 September 2018
Primary completion	5 December 2018
Estimated completion	10 January 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

communication type

Conditions studied

Positive Communication (Primary) — all drugs for Positive Communication (Primary) →
Negative Communication — all drugs for Negative Communication →
Control Condition — all drugs for Control Condition →

Sponsor

Swansea University

Who can join

18 and older, any sex, with Positive Communication (Primary) or Negative Communication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study explores how contextual effects in the fore of positive and negative communication can affect the effect of an osteopathic technique on pain pressure thresholds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Swansea University trials

Trials by the same sponsor.

NCT07452562 — Hesperidin RCT in MS · NA · recruiting
NCT07272096 — ACTing Minds: An ACT-based Videogame for Mental Health · NA · completed
NCT06961513 — Patient Evaluation of Treatment of Pelvic-floor Muscle Dysfunction. · not yet recruiting
NCT06698588 — Symptom-specific Effects of Omega-3 Across Neurodevelopmental Symptoms · NA · recruiting
NCT06407557 — Optimizing Older Adults' Home Space for Physical Activity · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03855254 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swansea University
Last refreshed: 26 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03855254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing